Pfizer has been granted FDA approval for BRAFTOVI® in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer with a BRAF V600E mutation. These are among the ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer last month, and it already has survival data that could see that ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi – encorafenib – in combination with ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 ...

Adding Pfizer’s cancer drug Braftovi to standard treatments helped people with a form of colorectal cancer live longer without their disease worsening than those who got the typical care alone ...

PFE offers a 6.73% dividend yield and growth potential, driven by strategic acquisitions, R&D, and discounted valuations.

Pfizer reported fourth-quarter 2024 adjusted ... driven by strong contributions from Padcev, Xtandi, Lorbrena and Braftovi/Mektovi. In Primary Care, alliance revenues and direct sales from Bristol ...